Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant dabrafenib + trametinib versus placebo after surgery for BRAF V600E/K-positive melanoma
RBR-9xrw6xPhase 3Completed
- Sponsor
- GSK
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabrafenib + trametinib and trametinib in cutaneous melanoma (CM) (2 arms), sponsored by GSK. Started Jan 2013; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on RBR-9xrw6x.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9xrw6x.